

Rossella Talotta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1641582/publications.pdf>

Version: 2024-02-01

34
papers

695
citations

687363

13
h-index

580821

25
g-index

34
all docs

34
docs citations

34
times ranked

1102
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical activity in idiopathic inflammatory myopathies: two intervention proposals based on literature review. <i>Clinical Rheumatology</i> , 2022, 41, 593-615.	2.2	4
2	Sequence complementarity between human noncoding RNAs and SARS-CoV-2 genes: What are the implications for human health?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166291.	3.8	5
3	Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159140.	2.4	10
4	The preventive and therapeutic role of physical activity in knee osteoarthritis. <i>Reumatismo</i> , 2022, 74, .	0.9	0
5	The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease. <i>Immunotherapy</i> , 2021, 13, 241-256.	2.0	16
6	Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases". <i>Clinical Immunology</i> , 2021, 224, 108665.	3.2	164
7	Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 52-60.	7.2	36
8	Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 546-554.	0.8	4
9	Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data. <i>Israel Medical Association Journal</i> , 2021, 23, 344-349.	0.1	2
10	Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 546-554.	0.8	8
11	Calcium physiology, metabolism and supplementation: a glance at patients with ankylosing spondylitis. <i>Reumatologia</i> , 2020, 58, 297-311.	1.1	4
12	The contribution of HERV clone 4 and other HERV members to the pathogenesis of rheumatic autoimmune diseases. <i>Apmis</i> , 2020, 128, 367-377.	2.0	9
13	Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 845-867.	4.1	3
14	JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. <i>Biomolecules</i> , 2020, 10, 1002.	4.0	97
15	Retroviruses in the pathogenesis of systemic lupus erythematosus: Are they potential therapeutic targets?. <i>Autoimmunity</i> , 2020, 53, 177-191.	2.6	7
16	Autoimmunity as the comet tail of COVID-19 pandemic. <i>World Journal of Clinical Cases</i> , 2020, 8, 3621-3644.	0.8	50
17	Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection. <i>American Journal of Clinical and Experimental Immunology</i> , 2020, 9, 73-80.	0.2	1
18	Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma?. <i>Cytokine and Growth Factor Reviews</i> , 2019, 49, 42-58.	7.2	2

#	ARTICLE	IF	CITATIONS
19	Psoriatic arthritis: From pathogenesis to pharmacologic management. <i>Pharmacological Research</i> , 2019, 148, 104394.	7.1	16
20	AB1106â€¦PREVALENCE AND EPIDEMIOLOGY OF FAMILIAL MEDITERRANEAN FEVER AND TUMOR NECROSIS FACTORRECEPTOR-ASSOCIATED PERIODIC SYNDROME: RESULTS FROM AN ITALIAN CENTER. , 2019, , .		0
21	Microbial Agents as Putative Inducers of B Cell Lymphoma in SjÃ¶rgrenâ€™s Syndrome through an Impaired Epigenetic Control: The State-of-The-Art. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	2.2	9
22	Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases. <i>Immunotherapy</i> , 2019, 11, 241-254.	2.0	23
23	Evaluation of salivary and plasma microRNA expression in patients with SjÃ¶rgren's syndrome, and correlations with clinical and ultrasonographic outcomes. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 70-77.	0.8	2
24	One year in review 2019: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 3-10.	0.8	9
25	Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 500-510.	3.3	37
26	Certainties and uncertainties concerning the contribution of pericytes to the pathogenesis of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 14-20.	1.7	4
27	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 945-956.	3.0	16
28	Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series. <i>Journal of Medical Case Reports</i> , 2018, 12, 154.	0.8	16
29	From autoinflammation to autoimmunity: old and recent findings. <i>Clinical Rheumatology</i> , 2018, 37, 2305-2321.	2.2	39
30	Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance. <i>Current Rheumatology Reviews</i> , 2018, 14, 131-139.	0.8	7
31	Measurement of Serum Klotho in Systemic Sclerosis. <i>Disease Markers</i> , 2017, 2017, 1-7.	1.3	7
32	The Microbiome in Connective Tissue Diseases and Vasculitides: An Updated Narrative Review. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	2.2	27
33	Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 17.	2.4	19
34	Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response. <i>Journal of Clinical Immunology</i> , 2015, 35, 550-557.	3.8	42